Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2023 Aug 1

PMID 37526188

Authors

Daniel J van Wamelen

Valentina Leta

K Ray Chaudhuri

Peter Jenner

Affiliations

Soon will be listed here.

Abstract

The symptomatic treatment of Parkinson's disease (PD) has been dominated by the use of dopaminergic medication, but significant unmet need remains, much of which is related to non-motor symptoms and the involvement of non-dopaminergic transmitter systems. As such, little has changed in the past decades that has led to milestone advances in therapy and significantly improved treatment paradigms and patient outcomes, particularly in relation to symptoms unresponsive to levodopa. This review has looked at how pharmacological approaches to treatment are likely to develop in the near and distant future and will focus on two areas: 1) novel non-dopaminergic pharmacological strategies to control motor symptoms; and 2) novel non-dopaminergic approaches for the treatment of non-motor symptoms. The overall objective of this review is to use a 'crystal ball' approach to the future of drug discovery in PD and move away from the more traditional dopamine-based treatments. Here, we discuss promising non-dopaminergic and 'dirty drugs' that have the potential to become new key players in the field of Parkinson's disease treatment.

References

Schapira A, Chaudhuri K, Jenner P . Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(8):509. DOI: 10.1038/nrn.2017.91. View

Sauerbier A, Jenner P, Todorova A, Chaudhuri K . Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S41-6. DOI: 10.1016/j.parkreldis.2015.09.027. View

Shetty A, Bates A . Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimer's and Parkinson's diseases. Brain Res. 2015; 1638(Pt A):74-87. PMC: 5313260. DOI: 10.1016/j.brainres.2015.09.019. View

Leta V, Jenner P, Chaudhuri K, Antonini A . Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update. Expert Opin Drug Saf. 2019; 18(12):1203-1218. DOI: 10.1080/14740338.2019.1681966. View

Tyagi R, Bisht R, Pant J, Kumar P, Majeed A, Prakash A . Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats. Exp Toxicol Pathol. 2014; 67(2):211-7. DOI: 10.1016/j.etp.2014.12.001. View

Araujo R, Aranda-Martinez J, Aranda-Abreu G . Amantadine Treatment for People with COVID-19. Arch Med Res. 2020; 51(7):739-740. PMC: 7290190. DOI: 10.1016/j.arcmed.2020.06.009. View

Rota S, Urso D, van Wamelen D, Leta V, Boura I, Odin P . Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?. Transl Neurodegener. 2022; 11(1):43. PMC: 9558383. DOI: 10.1186/s40035-022-00317-x. View

Stayte S, Vissel B . Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci. 2014; 8:113. PMC: 4033125. DOI: 10.3389/fnins.2014.00113. View

Halliday G, Blumbergs P, Cotton R, Blessing W, Geffen L . Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 1990; 510(1):104-7. DOI: 10.1016/0006-8993(90)90733-r. View

10.

Hattori N, Kikuchi M, Adachi N, Hewitt D, Huyck S, Saito T . Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2016; 32:73-79. DOI: 10.1016/j.parkreldis.2016.08.020. View

11.

Dulski J, Uitti R, Ross O, Wszolek Z . Genetic architecture of Parkinson's disease subtypes - Review of the literature. Front Aging Neurosci. 2022; 14:1023574. PMC: 9632166. DOI: 10.3389/fnagi.2022.1023574. View

12.

Jenner P . Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. 2000; 247 Suppl 2:II43-50. DOI: 10.1007/pl00007760. View

13.

BIRCHFIELD R . Levodopa: problems, promise, patience and persistence. Northwest Med. 1970; 69(8):561-3. View

14.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano C . Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. J Pharmacol Exp Ther. 2018; 367(3):442-451. DOI: 10.1124/jpet.118.251645. View

15.

Altwal F, Moon C, West A, Steiner H . The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. 2020; 9(10). PMC: 7600385. DOI: 10.3390/cells9102265. View

16.

Hodgson R, Bertorelli R, Varty G, Lachowicz J, Forlani A, Fredduzzi S . Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of.... J Pharmacol Exp Ther. 2009; 330(1):294-303. DOI: 10.1124/jpet.108.149617. View

17.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A . Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015; 30(7):919-27. PMC: 4855523. DOI: 10.1002/mds.26170. View

18.

Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R . Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study. Mov Disord. 2015; 30(10):1343-50. DOI: 10.1002/mds.26286. View

19.

Hauser R, Stocchi F, Rascol O, Huyck S, Capece R, Ho T . Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015; 72(12):1491-500. DOI: 10.1001/jamaneurol.2015.2268. View

20.

Schiess , Zheng , Soukup , Bonnen , Nauta . Parkinson's disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord. 2000; 6(2):69-76. DOI: 10.1016/s1353-8020(99)00051-6. View